3-乙酰胺基-4甲基苯甲酸 | 6946-14-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-乙酰胺基-4甲基苯甲酸
• 英文名称: 3-acetamido-4-methylbenzoic acid
• CAS: 6946-14-1
• 化学式: C₁₀H₁₁NO₃
• mdl: MFCD00020381
• 分子量: 193.202
• InChiKey: FGHGVZVGAYQACH-UHFFFAOYSA-N

物化性质

• 熔点：
  267-270 °C (decomp)
• 沸点：
  425.7±33.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Acetamido-4-methylbenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Acetamido-4-methylbenzoic acid
CAS number: 6946-14-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H11NO3
Molecular weight: 193.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-乙酰胺基-4甲基苯甲酸 在 氯化亚砜 、 氰胺 、 硝酸 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 72.0h， 生成 尼罗替尼
  参考文献：
  名称：

  一种尼洛替尼的高收率合成方法

  摘要：

  本发明公开了一种尼洛替尼的高收率合成方法，涉及药物有机合成技术领域，以3‑乙酰胺基‑4‑甲基苯甲酸作为起始原料，与3‑(4‑甲基‑1H‑咪唑‑1‑基)‑5‑三氟甲基苯胺经酰胺缩合反应得到中间体I，中间体I与单氰胺经加成反应得到中间体II，中间体II与3‑二甲氨基‑1‑(3‑吡啶基)‑2‑丙烯‑1‑酮经闭环反应得到尼洛替尼。本发明原料易得，在简化反应操作的同时降低成本投入，减少三废产生量，提高起始原料和中间体的转化率，所制尼洛替尼的总收率能够达到70％以上。

  公开号：

  CN110872279B
• 作为产物：
  描述：

  3-氨基-4-甲基苯甲腈 在 sodium hydroxide 、 硫酸 、 双氧水 、 sodium nitrite 作用下， 生成 3-乙酰胺基-4甲基苯甲酸
  参考文献：
  名称：

  Yasue et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1957, vol. 77, p. 1048

  摘要：

  DOI：

文献信息

• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• [EN] NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125530A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及一种公式（I）的药物制剂，用于治疗和/或预防哺乳动物中的疾病，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK，也称为MAP3K14）的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain
  作者：René Blöcher、Karen M. Wagner、Raghavender R. Gopireddy、Todd R. Harris、Hao Wu、Bogdan Barnych、Sung Hee Hwang、Yang K. Xiang、Ewgenij Proschak、Christophe Morisseau、Bruce D. Hammock

  DOI：10.1021/acs.jmedchem.7b01804

  日期：2018.4.26

  enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(tri

  受先前发现的可溶性环氧化物水解酶 (sEH) 和磷酸二酯酶 4 (PDE4) 抑制剂增强镇痛功效的启发，我们设计、合成并表征了 21 种新型 sEH/PDE4 双重抑制剂。其中最好的在体外试验中显示出良好的功效。对四种选定化合物的子集的进一步药代动力学研究导致鉴定出生物可利用的双重抑制剂N -(4-甲氧基-2-(三氟甲基)苄基)-1-丙酰哌啶-4-甲酰胺 ( MPPA )。在脂多糖诱导的炎症性疼痛大鼠模型中，口服 3 mg/kg 后，血液中的MPPA迅速增加（ T max = 30 分钟；C max = 460 nM），并减少炎症疼痛，且起效迅速，与血液水平相关4小时的时间过程。此外，MPPA不会改变患有炎性疼痛的大鼠的自我激励探索或对照大鼠的戒断潜伏期。
• 一种拉多替尼的高收率合成方法
  申请人：安徽峆一药业股份有限公司

  公开号：CN111039932B

  公开（公告）日：2023-09-12

  本发明公开了一种拉多替尼的高收率合成方法，涉及药物有机合成技术领域，以3‑乙酰胺基‑4‑甲基苯甲酸作为起始原料，与3‑(4‑甲基‑1H‑咪唑‑1‑基)‑5‑三氟甲基苯胺经酰胺缩合反应得到中间体I，中间体I与单氰胺经加成反应得到中间体II，中间体II与二甲氨基‑1‑(3‑吡嗪基)‑2‑丙烯‑1‑酮经闭环反应得到拉多替尼；本发明在简化反应操作的同时降低成本投入，减少三废产生量，提高起始原料和中间体的转化率，所制拉多替尼的总收率能够达到79％以上。
• Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
  申请人：——

  公开号：US20040167194A1

  公开（公告）日：2004-08-26

  6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile, and the anhydrous monoacetate salt thereof, are useful in the treatment of alpha-2 mediated disorders such as ocular hypertension.

  6-[(4,5-二氢-1H-咪唑-2-基)氨基]-7-甲基-1H-苯并咪唑-4-羧腈在2,3,7-三氨基-4,6-二甲基-1,9-苝二羧腈和其无水单乙酸盐的情况下，可用于治疗α-2介导的疾病，如眼压高。